ProCE Banner Activity

CE

The Pharmacist’s Role in Improving Medication Adherence to Oral SERD Therapy in HR+/HER2- Breast Cancer

Clinical Thought

Read my commentary to learn how I promote adherence to oral SERD therapy in my patients with HR+/HER2- breast cancer, including strategies to mitigate and manage toxicities associated with oral SERD therapy.

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: February 23, 2024

Expiration: February 22, 2025

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Provided by

Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange and ProCE, LLC.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Practicing Clinicians Exchange

ProCE Banner

ProCE, LLC

ProCE Banner

Target Audience

This program is intended for oncology pharmacists, and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners to optimize clinical benefit by maintaining adherence and persistence with oral SERDs in the treatment of patients with HR+/HER2- breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan treatment for patients with HR+/HER2- MBC progressing on first line endocrine therapy with or without CDK4/6 inhibitor based on individual patient and disease characteristics, genomic profile, available clinical data, new approvals, and expert recommendations

  • Mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer

  • Implement recommended strategies to improve adherence to oral SERD therapy in patients with HR+/HER2- breast cancer

  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy for the prescribed duration of treatment in patients with HR+/HER2- breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC, Practicing Clinicians Exchange (PCE), and ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 23, 2024, through February 22, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-067-H01-P 

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.